Top Markets
#1 Siren Siren +34.93%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.13%
#3 Cysic Cysic +18.09%
#4 Ribbita by Virtuals Ribbita by Virtuals +17.74%
#5 PulseChain PulseChain +17.52%
#6 TROLL TROLL +17.09%
#7 KUB Coin KUB Coin +15.67%
#8 OpenEden OpenEden +15.56%
#9 BasedHype BasedHype +14.48%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +14.44%
Coin of the day
Siren Siren
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Skye Bioscience, Inc. Skye Bioscience, Inc.

Skye Bioscience, Inc.

SKYE
Rangering i aksjer #31353
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on... Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
Aksjekurs
$0.4018
Markedsverdi
$14.12M
Endring (1 dag)
-3.20%
Endring (1 år)
-88.15%
Land
US
Handel Skye Bioscience, Inc. (SKYE)

Kategori

Healthcare
Inntekter for Skye Bioscience, Inc. (SKYE)
Inntekter i 2026 TTM: 0
Ifølge Skye Bioscience, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Skye Bioscience, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE